Filing summary
Important identity and period mismatch: The supplied filing is for Knight Knox Development Corp., not Artelo Biosciences, Inc. It is a Form 10-K for the fiscal year ended August 31, 2015, not a quarterly report for “2015 Q4.”
Business context
Knight Knox was a pre-revenue, development-stage company planning an online classified and auction marketplace for European and American users. Its proposed site, offeritnow.com, was not yet fully developed or operational. The company described itself as a shell company and reported no customers or employees; its sole officer and director was James Manley.
Financial performance and liquidity
| Metric | FY ended Aug. 31, 2015 | FY ended Aug. 31, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses and net loss | $15,241 | $15,269 |
| Cash used in operations | $13,502 | $15,269 |
| Cash at year-end | $17,029 | $14,731 |
| Current liabilities | $1,739 | $0 |
| Working capital | $15,290 | $14,731 |
| Long-term debt | $0 | $0 |
2015 expenses included $14,732 of professional fees and $509 of general and administrative costs. Financing provided $15,800 from share issuance during the year; a further $600 subscription receivable was outstanding at year-end. The company reported an accumulated deficit of $30,510 and stockholders’ equity of $15,290. No investing cash flows, dividends, or material capital expenditure commitments were reported. Operating margins are not meaningful because there was no revenue.
Changes versus prior year
Net loss declined by $28, while operating cash use fell by $1,767. Professional fees rose from $11,000 to $14,732, while general and administrative costs declined from $4,269 to $509. Year-end cash increased by $2,298, supported by equity financing; current liabilities rose from zero to $1,739. Shares outstanding increased from 6,000,000 to 7,640,000.
Outlook, risks and unusual items
Management planned to raise additional capital through equity offerings, loans, or support from management and significant shareholders, and proposed charging 5% transaction fees on marketplace sales and selling advertising. No revenue forecast or quantified operating guidance was provided. Management said available cash was insufficient to fund business development over the next 12 months, despite also stating it could cover regulatory reporting costs for that period. The auditor identified substantial doubt about the company’s ability to continue as a going concern; further financing was uncertain and could dilute existing shareholders.
Competition was described as significant, with low barriers to entry and established rivals including eBay and Amazon. Website development depended on contractors without a development contract. The company reported ineffective disclosure controls and internal control over financial reporting, citing no audit committee, no independent directors, inadequate segregation of duties, and management concentration in one individual. No pending litigation or commitments and contingencies were reported. The stock had been approved for OTC Pink quotation but had not traded as of October 13, 2015.
Important facts for investors to verify
- Confirm that this Knight Knox filing is the intended document; it does not identify Artelo Biosciences.
- Confirm the fiscal-year period: the filing covers the year ended August 31, 2015.
- Verify cash availability, the collection of the $600 subscription receivable, and funding needs after year-end.
- Assess the going-concern uncertainty, financing prospects, and potential dilution.
- Check whether the proposed website became operational and whether the material weaknesses in controls were remediated.